Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →. With University of Southern Denmark.
Phase
—
Status
Completed
Study type
Observational
Enrollment
194,928actual
Sites
1
Country
Denmark
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-26 | actual | When the study began enrolling |
| Primary completion | 2025-11-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-25 | actual | The whole study's end, after follow-up |
| First posted | 2020-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Ozempic®
- Drug: Active Comparator
- Drug: Rybelsus®
Primary outcome
what the primary-completion date above is the date OFOccurrence of first time malignant neoplasm of pancreas
measured From when semaglutide entered the market in Denmark, Sweden, and Norway (Q3/Q4 2018) until December 31, 2023
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed